Vancouver, British Columbia – TheNewswire - October 21, 2022 – Cava Healthcare Inc. (the "Company") is pleased to announce announce completion of its Annual General and Special Meeting of Shareholders, held on October 12th, 2022 (the “Meeting”).  The Meeting received the audited financial statements of the Company for the financial years ended September 30, 2020 and September 30, 2021, together with the auditor’s reports thereon.  The Company’s shareholders (the “Shareholders”) voted to set the number of Directors at seven, and elected Dr. Wilfred Jefferies, Mr. Theo Warkentin, Dr. Adrian Wade, Ms. Roslyn Ritchie-Derrien, Dr. Terry Pearson, Mr. James Borkowski and Ms. Jamie Elizabeth Kirwin as Directors for the ensuing year. The Shareholders then
re-appointed MNP LLP, Chartered Professional Accountants, as Auditor of the Company for the ensuing year and authorized the Directors to fix their renumeration. Shareholders also passed a New Articles Resolution cancelling the existing form of articles and adopting the new form of articles bringing the Company up-to date with current corporate practices under the Business Corporations Act (British Columbia).  No other business was brought before the Meeting by its Shareholders.

Of the seven directors appoint, three directors (Dr. Terry Pearson, Mr. James Borkowski and Ms. Jamie Kirwin) are considered to be independent.

Mr. Theo Warkentin stated “The Board of Directors and management of the Company wish to thank all of the Shareholders for their continued support throughout the years.   We look forward to an exciting future for the Company as we continue to advance our promising technologies”.

For further information, please contact Theo Warkentin at theo@cavahealthcare.ca or (604) 726‑1435.

On Behalf of the Board of Directors

Theo Warkentin
CEO and Director

CAVA IS FOCUSED ON ENHANCING OPTIMAL HEALTH BY PREDICTING, PREVENTING AND ALLEVIATING DISEASE

Cava is a specialty biotechnology company focused on advancing drug development to address unmet medical needs in neurodegeneration, inflammation and restoration of immune function.  The Company has a patent protected portfolio of intellectual property and technology, concentrated on the development of a treatment for Alzheimer’s Disease and various oncology related biomarkers and treatments.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995.  All statements in this press release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, matters related to the Company’s current and planned research and development programs, including in respect of the prosecution and maintenance of the patent portfolio, and the Company's prospect of success in executing its proposed plans.  Often, but not always, forward-looking statements can be identified by words such as “will”, “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved.  Forward-looking statements are based on certain assumptions regarding the Company, including, without limitation, expected growth, results of operations and research and development activities (including in respect of the patent portfolio), results of operations, performance, industry trends, growth opportunities, and that the Company will be able to obtain the financing required to carry out its planned future business activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.

Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the actual results of research and development programs, the inability of the Company, to, among other things, protect its intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, commercialize any therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and development programs as planned, and obtain the financing required to carry out its planned future activities.  Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the Company's industries may also adversely affect the future results or performance of the Company.  These forward-looking statements are made as of the date of this press release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements.  Although the Company believes that the statements, beliefs, plans, expectations, intentions and assumptions contained in this press release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations intentions or assumptions will prove to be accurate.  Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time.  These reports and the Company’s filings are available at www.sedar.com.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.